|
|
|
||
Last update: RNDr. Ondřej Vaněk, Ph.D. (19.02.2024)
A special interest is given to practical examples - each lecture contains, besides the part from the main topic, a part describing one example of a therapeutically used protein, with a review of its research, development, and current usage. Lectures are delivered in English. Depending on the number of students enrolled, the course can be arranged as lectures or in another way (colloquium, consultations). |
|
||
Last update: RNDr. Ondřej Vaněk, Ph.D. (19.02.2024)
Biopharmaceutical benchmarks. Walsh G. Nat Biotechnol. 18 (2000): 831-833. Biopharmaceutical benchmarks 2003. Walsh G. Nat Biotechnol. 21 (2003): 865-870. Biopharmaceutical benchmarks 2006. Walsh G. Nat Biotechnol. 24 (2006): 769-776. Biopharmaceutical benchmarks 2010. Walsh G. Nat Biotechnol. 28 (2010): 917-924. Biopharmaceutical benchmarks 2014. Walsh G. Nat Biotechnol. 32 (2014): 992-1000. Biopharmaceutical benchmarks 2018. Walsh G. Nat Biotechnol. 36 (2018): 1136-1145. Biopharmaceutical benchmarks 2022. Walsh G. Nat Biotechnol. 40 (2022): 1722-1760. Expression systems. Dyson M. R., Durocher, Y. eds. Bloxham, Scion Publishing Ltd., 2007 |
|
||
Last update: RNDr. Ondřej Vaněk, Ph.D. (20.04.2021)
The exam will consist of a written part (test) and an oral part (discussion of the test and related questions). |
|
||
Last update: RNDr. Ondřej Vaněk, Ph.D. (19.02.2024)
Introduction to protein therapeutics: review of current and future market, ways of approval. Modern methods of recombinant protein expression: overview, choosing the right expression host. Cloning with and without restriction endonucleases. Prokaryotic expression systems: pros and cons, news and techniques. Eukaryotic expression systems: yeast, protozoa, plant expression systems, and insect cells. Protein production in mammalian cell lines: stable and transient transfection, selection and yield improvement, cell line engineering. Monoclonal antibodies and their recombinant fragments. Hormones, cytokines, and other small therapeutics. Recombinant vaccines: boons and risks. New alternative protein binding scaffolds: (not only) alternatives to antibodies. Therapeutic protein modifications: conjugation with polymers, solid phase depot formulation, administration issues of protein solutions, protein radioconjugates. |
|
||
Last update: RNDr. Ondřej Vaněk, Ph.D. (16.02.2012)
Your interest in the lecture topic:-) |